

1 **Supplementary material**

2

3 **Supplementary Table 1.** Details of missing values and imputation status.

4 **Supplementary Figure 1.** Frequency of prior anticoagulation therapy as compared to
5 no prior anticoagulation in patients with intracerebral hemorrhage from 2013 to 2019.

6 **Supplementary Figure 2.** Functional outcome at 3 months using modified Rankin
7 Scale (mRS) according to prior anticoagulation therapy as compared to no prior
8 anticoagulation in patients with intracerebral hemorrhage.

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27 **Supplementary table 1.** Details of missing values and imputation status.

Characteristic	Total (n=11,349)	Switzerland (n=3,500)	Norway (n=7,849)	Multiple imputation (yes/no)
	Missing values, n (%)			
Demographics				
Age	235 (2.07)	235 (6.71)	0 (0.00)	yes
Sex	9 (0.08)	9 (0.26)	0 (0.00)	yes
Country	0 (0.00)	0 (0.00)	0 (0.00)	no
Risk factors				
Diabetes	423 (3.73)	348 (9.94)	75 (0.96)	yes
Atrial fibrillation	324 (2.85)	214 (6.11)	110 (1.40)	yes
Concomitant medication				
Antiplatelets	307 (2.71)	279 (7.97)	28 (0.36)	yes
Antihypertensives	3,490 (30.75)	2,722 (77.77)	768 (9.78)	yes
Lipid lowering drugs	3,038 (26.77)	2,992 (85.49)	46 (0.59)	yes
DOAC type	173 (1.52)	1 (0.03)	172 (2.19)	no
Medical history				
History of ischemic stroke	258 (2.27)	209 (5.97)	49 (0.62)	yes
History of ICH	259 (2.28)	210 (6.00)	49 (0.62)	yes
History of coronary heart disease/ Myocardial infarction	3,116 (27.46)	3,023 (86.37%)	93 (1.18)	yes
Pre-stroke disability				
Pre-mRS	3,443 (30.34)	2,809 (80.26)	634 (8.08)	yes
Clinical presentation on admission				
NIHSS on admission	3,356 (29.57)	421 (12.03)	2,935 (37.39)	yes/no ^a
Level of consciousness at admission	194 (1.71)	117 (3.34)	77 (0.98)	yes/no ^b
Treating hospital level				
Treatment at stroke center	0 (0.00)	0 (0.00)	0 (0.00)	no
Local management				
Treatment at high-dependency unit	36 (0.32)	36 (1.03)	0 (0.00)	yes
Outcomes				
Functional outcome (mRS) at 3 months	2,703 (23.82)	591 (16.89)	2,112 (26.91)	no
Mortality at 3 months	410 (3.61)	410 (11.71)	0 (0.00)	no

28

29 ^a Not imputed for quantile (NIHSS) regression model.30 ^b Not imputed for binary multiple (LOC) regression model.


31 DOAC(s), direct oral anticoagulant(s); ICH, intracerebral hemorrhage; LOC, level of
32 consciousness; mRS, modified Rankin Scale; NIHSS, National Institutes of Health
33 Stroke Scale.

34


35 **Supplementary Figure 1.** Frequency of prior anticoagulation therapy as compared to
36 no prior anticoagulation in patients with intracerebral hemorrhage from 2013 to 2019.
37 (A) Combined data from Switzerland and Norway (n=11,349 patients). (B) Data from
38 Switzerland (n=3,500 patients). (C) Data from Norway (n=7,849 patients). DOACs,
39 direct oral anticoagulants; OACs, oral anticoagulants; VKAs, Vitamin K antagonists.

40


A Combined data from Switzerland and Norway



B Switzerland



C Norway




Legend: No OACs (grey), VKAs (red), DOACs (blue)

41

42

43 **Supplementary Figure 2.** Functional outcome at 3 months using modified Rankin
 44 Scale (mRS) according to prior anticoagulation therapy as compared to no prior
 45 anticoagulation in patients with intracerebral hemorrhage. (A) Combined data from
 46 Switzerland and Norway (n=6,903 patients). (B) Data from Switzerland (n=2,755
 47 patients). (C) Data from Norway (n=4,148 patients). Figure includes only sites with
 48 $\geq 70\%$ availability of mRS at 3 months. OACs, oral anticoagulants; VKAs, Vitamin-K-
 49 antagonists; DOACs, direct oral anticoagulants; mRS, modified Rankin Scale.

50



51